\chapter{Supplementary Tables} %\label{appendix-b}
%
\thispagestyle{plain}
\dsp
%
    \begin{center}
        \begin{longtable}{| p{.2\textwidth} | p{.60\textwidth} | p{.1\textwidth} |} \hline
            Name & Sequence & Purity\textsuperscript{\#} \\
            \hline
            CKII3K & H\textsubscript{2}N--KKKYPGGSTPVS\textsuperscript{$\ddagger$}SANMM--OH & 95\% \\ \hline %CKII 
            S10-35 & H\textsubscript{2}N--KKKY\underline{V}RVCSNPPCST\textsuperscript{11} \ldots HETGTTNTATTATSNMAGQH--OH & 91\% \\ \hline %S10
            \hline
            26mer &  H\textsubscript{2}N--\underline{V}RVCSNPPCET\textsuperscript{11} HETGTTNTATTATSN--OH & 98\% \\ \hline %WT-rep2
            C9R-26 & H\textsubscript{2}N--\underline{V}RVCSNPPRET\textsuperscript{11} HETGTTNTATTATSN--OH & 96\% \\ \hline %C9R-26mer
            C9S-26 & H\textsubscript{2}N--\underline{V}RVCSNPPSET\textsuperscript{11} HETGTTNTATTATSN--OH & 96\% \\ \hline %C9S-26mer
            C9Y-26 & H\textsubscript{2}N--\underline{V}RVCSNPPYET\textsuperscript{11} HETGTTNTATTATSN--OH & 96\% \\ \hline %C9Y-26mer
            C9A-26 & H\textsubscript{2}N--\underline{V}RVCSNPPAET\textsuperscript{11} HETGTTNTATTATSN--OH & 96\% \\ \hline %C9A-26mer
            C9NH\textsubscript{2}-26 & H\textsubscript{2}N--\underline{V}RVCSNPPA\textsuperscript{$\dagger$}ET\textsuperscript{11} HETGTTNTATTATSN--OH & 96\% \\ \hline 
            %C9aminoA-26mer
            A10-26 & H\textsubscript{2}N--\underline{V}RVCSNPPCAT\textsuperscript{11} HETGTTNTATTATSN--OH & 98\% \\ \hline %E10A-26mer
            Q10-26 & H\textsubscript{2}N--\underline{V}RVCSNPPCQT\textsuperscript{11} HETGTTNTATTATSN--OH & 98\% \\ \hline %E10A-26mer
            %
            \hline
            %
            32mer &  H\textsubscript{2}N--Y\underline{V}RVCSNPPCET\textsuperscript{11} \ldots HETGTTNTATTATSNMAGQH--OH & 89 (98)\% \\ \hline %WT-rep2+5 
            37mer &  H\textsubscript{2}N--Y\underline{V}RVCSNPPCET\textsuperscript{11} \ldots HETGTTNTATTATSNMAGQHGCSNP--OH & 89\% \\ \hline %WT-rep2+10    
            E10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPCET\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 98\% \\ \hline %base peptide
            A9E10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPAET\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 96\% \\ \hline %C9A
            R9E10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPRET\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 95\% \\ \hline %C9R
            S9E10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPSET\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 98\% \\ \hline %C9R
            E10V11-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPCEV\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 96\% \\ \hline %T11V
            A10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPCAT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 97\% \\ \hline %A10
            D10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPCDT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 96\% \\ \hline %D10
            A9D10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPADT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 96\% \\ \hline %A9D10
            R9D10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPRDT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 98\% \\ \hline %R9D10
            S9D10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPSDT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 95\% \\ \hline %S9D10
            isoD10-32 & H\textsubscript{2}N--Y\underline{V}RVCSNPPCisoDT\textsuperscript{11} \ldots HQTGTTNTATTATSNMAGQH--NH\textsubscript{2} & 99\% \\ \hline %E10D
            \hline 
            N-term & H\textsubscript{2}N--YVRVCSNPPC--OH & 99\% \\ \hline %Nterm
            N\textsuperscript{*} & H\textsubscript{2}N--YVR\textsuperscript{*}VCSNPPC--OH & 99\% \\ \hline %N*
            HCF-C & H\textsubscript{2}N--T\textsuperscript{11}HETGTTNTATTATSN--OH & 98\% \\ \hline %HCF-C
            %
            \caption[List of peptides employed in these studies]{List of peptides employed in these studies. Peptides were all obtained from Biomatik. Notes:~\textsuperscript{\#} parenthetical value is for separate batch upon re-order.~\textsuperscript{$\ddagger$} denotes site of principle glycosylation.\cite{Lazarus:2011ip} ~\textsuperscript{*} denotes heavy Arg: 6$\times$\textsuperscript{13}C + 4$\times$\textsuperscript{15}N (+10 Da).~\underline{V} denotes the first numbered residue, to maintain convention with HCF-1 literature; Residue X\textsuperscript{11} is labeled for convenience. A\textsuperscript{$\dagger$} denotes a non-canonical amino alanine residue.}
            \label{tab:listofpeptides}
        \end{longtable}
    \end{center}
%HCF-AAA was made by MBL; DNA for EEE, EAA, AEA, AAA and SAA were obtained from Jiaoyang Jiang/Mike Lazarus and subsequent constructs were subcloned.
\newpage
            %HCF-3R-EEE & X\textsuperscript{A} = E; X\textsuperscript{B} = E; X\textsuperscript{C} = E\\ \hline
            %HCF-3R-EAA & X\textsuperscript{A} = E; X\textsuperscript{B} = A; X\textsuperscript{C} = A\\ \hline
            %HCF-3R-AEA & X\textsuperscript{A} = A; X\textsuperscript{B} = E; X\textsuperscript{C} = A\\ \hline
            %HCF-3R-AAE & X\textsuperscript{A} = A; X\textsuperscript{B} = A; X\textsuperscript{C} = E\\ \hline
            %\hline \hline
            %HCF-3R-XXX & M\textsuperscript{1}AHHHHHHHHSAALEVLFQGPGYQDPPGTV \ldots
            %\underline{TLVCSNPPC\textbf{X\textsuperscript{A}}THETGTTNTATTTVVA} \ldots
            %NLGGHPQPTQVQFVCDRQEAAASLVT \ldots
            %STVGQQNGSV\underline{VRVCSNPPC\textbf{X\textsuperscript{B}}THETGT} \ldots 
            %\underline{TNTATTATSN}MAG\underline{QHGCSNPPC\textbf{X\textsuperscript{C}}THE} \ldots
            %\underline{TGTTNTATTAMSS}VGAN\textsuperscript{151}\\ 
    \begin{center}
         \begin{longtable}{|c|c|c|}
            \hline
            Strain & Construct\textsuperscript{$\ddagger$} & Plasmid \\ \hline
            JCJ-C119 & HCF-3R-EEE\textsuperscript{$\dagger$} (where X\textsuperscript{$\alpha$} = X\textsuperscript{$\beta$} = X\textsuperscript{$\gamma$} = E) & pET47b \\ \hline
            JCJ-C146 & HCF-3R-EAA\textsuperscript{$\dagger$} (where X\textsuperscript{$\alpha$} = E; X\textsuperscript{$\beta$} = X\textsuperscript{$\gamma$} = A) & pET47b \\ \hline
            JCJ-C147 & HCF-3R-AEA\textsuperscript{$\dagger$} (where X\textsuperscript{$\beta$} = E ; X\textsuperscript{$\alpha$} = X\textsuperscript{$\gamma$} = A) & pET47b \\ \hline
            JCJ-C150 & HCF-3R-AAE (where X\textsuperscript{$\alpha$} = X\textsuperscript{$\beta$} = A; X\textsuperscript{$\gamma$} = E) & pET47b \\ \hline
        \caption[HCF-3R-XXX constructs]{HCF-3R-XXX constructs.~\textsuperscript{$\dagger$}Allele originally made by Michael B. Lazarus/Jiaoyang Jiang.~\textsuperscript{$\ddagger$}Generic sequence for HCF-1-EAA (C9X) is as follows:\\
        MAHHHHHHHHSAALEVLFQGPGYQDPPGTV\underline{TLVCSNPPC\textbf{X\textsuperscript{$\alpha$}}THETGTTNTATTTVVA}\\ \ldots NLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSV\underline{VRVCSNPPC\textbf{X\textsuperscript{$\beta$}}THETGTTN}\\ \ldots \underline{TATTATSN}MAG\underline{QHGCSNPPC\textbf{X\textsuperscript{$\gamma$}}THETGTTNTATTAMSS}VGAN.\\Each underlined region denotes HCF-1 cleavage repeats one, two and three, respectively.}
        \label{tab:listhcf3rxxx}
        \end{longtable}
    \end{center}
\newpage

    \begin{center}
         \begin{longtable}{|c|c|c|}
            \hline
            Strain & Construct\textsuperscript{$\ddagger$} & Plasmid \\
            %HCF-3R-(C9X)EAA & MAHHHHHHHHSAALEVLFQGPGYQDPPGTV \ldots\underline{TLVCSNPP\textbf{X}ETHETGTTNTATTTVVA} \ldots
            %NLGGHPQPTQVQFVCDRQEAAASLV \ldots TSTVGQQNGSVVRVCSNPPCATH \ldots ETGTTNTATTATSNMAGQHGCSNPP \ldots CATHETGTTNTATTAMSSVGAN\\
            \hline
            JCJ-C169 & HCF-3R-EAA (C9A); X = A & pET47b \\ \hline
            JCJ-C160 & HCF-3R-EAA (C9M); X = M & pET47b \\ \hline
            JCJ-C170 & HCF-3R-EAA (C9S); X = S & pET47b \\ \hline
            JCJ-C159 & HCF-3R-EAA (C9T); X = T & pET47b \\ \hline
            JCJ-C167 & HCF-3R-EAA (C9R); X = R & pET47b \\ \hline
            JCJ-C165 & HCF-3R-EAA (C9V); X = V & pET47b \\ \hline
            JCJ-C166 & HCF-3R-EAA (C9D); X = D & pET47b \\ \hline
            JCJ-C195 & HCF-3R-EAA (C9K); X = K & pET47b \\ \hline
            JCJ-C193 & HCF-3R-EAA (C9E); X = E & pET47b \\ \hline
            JCJ-C196 & HCF-3R-EAA (C9Y); X = Y & pET47b \\ \hline
        \caption[HCF-3R-EAA (C9X) constructs]{HCF-3R-EAA (C9X) constructs.~\textsuperscript{$\ddagger$}Generic sequence for HCF-1-EAA (C9X) is as follows:\\
        MAHHHHHHHHSAALEVLFQGPGYQDPPGTV\underline{TLVCSNPP\textbf{X}ETHETGTTNTATTTVVA}\\ \ldots NLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSVVRVCSNPPCATHETGTTN\\
        \ldots TATTATSNMAGQHGCSNPPCATHETGTTNTATTAMSSVGAN}
        \label{tab:listhcf3rc9}
        \end{longtable}
    \end{center}
    %
    \newpage
    %
    %& HCF-3R-EAA(T11X) & MAHHHHHHHHSAALEVLFQGPGYQDPPGTV \ldots\underline{TLVCSNPPCE\textbf{X}HETGTTNTATTTVVA} \ldots
    %NLGGHPQPTQVQFVCDRQEAAASLV \ldots TSTVGQQNGSVVRVCSNPPCATH \ldots ETGTTNTATTATSNMAGQHGCSNPP \ldots CATHETGTTNTATTAMSSVGAN & \\
    \begin{center}
         \begin{longtable}{|c|c|c|}
            \hline
            Strain & Construct\textsuperscript{$\ddagger$} & Plasmid \\ \hline
            JCJ-C163 & HCF-3R-EAA (T11M); X = M & pET47b \\ \hline
            JCJ-C164 & HCF-3R-EAA (T11A); X = A & pET47b \\ \hline
            JCJ-C168 & HCF-3R-EAA (T11N); X = N & pET47b \\ \hline
            JCJ-C162 & HCF-3R-EAA (T11I); X = I & pET47b \\ \hline
            JCJ-C161 & HCF-3R-EAA (T11V); X = V & pET47b \\ \hline
            JCJ-C183 & HCF-3R-EAA (T11S); X = S & pET47b \\ \hline
        \caption[HCF-3R-EAA (T11X) constructs]{HCF-3R-EAA (T11X) constructs.~\textsuperscript{$\ddagger$}Generic sequence for HCF-1-EAA (T11X) is as follows:\\
        MAHHHHHHHHSAALEVLFQGPGYQDPPGTV\underline{TLVCSNPPCE\textbf{X}HETGTTNTATTTVVA}\\ \ldots NLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSVVRVCSNPPCATHETGTTN\\
        \ldots TATTATSNMAGQHGCSNPPCATHETGTTNTATTAMSSVGAN}
        \label{tab:listhcf3rt11}
        \end{longtable}
    \end{center}
    %
    \newpage
    %
    \begin{center}
         \begin{longtable}{|c|c|c|}
            \hline
            Strain & Construct\textsuperscript{$\ddagger$} & Plasmid \\ \hline
            %HCF-3R-XAA & MAHHHHHHHHSAALEVLFQGPGYQDPPGTV \ldots\underline{TLVCSNPPC\textbf{X}THETGTTNTATTTVVA} \ldots
            %NLGGHPQPTQVQFVCDRQEAAASLV \ldots TSTVGQQNGSVVRVCSNPPCATH \ldots ETGTTNTATTATSNMAGQHGCSNPP \ldots CATHETGTTNTATTAMSSVGAN\\
            \hline \hline
            JCJ-C120 & HCF-3R-AAA\textsuperscript{$\dagger$}; X = A & pET47b \\ \hline
            JCJ-C154 & HCF-3R-SAA\textsuperscript{$\dagger$}; X = S & pET47b \\ \hline
            JCJ-C209 & HCF-3R-DAA; X = D & pET47b \\ \hline
            JCJ-C211 & HCF-3R-NAA; X = N & pET47b \\ \hline
            JCJ-C210 & HCF-3R-QAA; X = Q & pET47b \\ \hline
        \caption[HCF-3R-XAA constructs]{HCF-3R-XAA constructs.~\textsuperscript{$\dagger$}Allele originally made by Michael B. Lazarus/Jiaoyang Jiang. \textsuperscript{$\ddagger$}Generic sequence for HCF-1-XAA (E10X) is as follows:\\
        MAHHHHHHHHSAALEVLFQGPGYQDPPGTV\underline{TLVCSNPPC\textbf{X}THETGTTNTATTTVVA}\\ \ldots NLGGHPQPTQVQFVCDRQEAAASLVTSTVGQQNGSVVRVCSNPPCATHETGTTN\\
        \ldots TATTATSNMAGQHGCSNPPCATHETGTTNTATTAMSSVGAN} 
        \label{tab:listhcf3re10}
        \end{longtable}
    \end{center}   
%
\newpage
%
    \begin{center}
         \begin{longtable}{|c|c|c|c|}
            \hline
            Strain & Construct & Residues\textsuperscript{$\ddagger$} & Plasmid\\ \hline
            JCJ-C121 & C14 & 1--56 & pET47b \\ \hline
            JCJ-C122 & C15 & 1--92 & pET47b \\ \hline
            JCJ-C131 & C16 & 1--118 & pET47b \\ \hline
            JCJ-C123 & C17 & 1--30 $\|$ 57--151 & pET47b \\ \hline
            JCJ-C137 & C18 & 1--30 $\|$ 57--118 & pET47b \\ \hline
            JCJ-C132 & C19 & 1--30 $\|$ 93--151 & pET47b \\ \hline
            JCJ-C124 & C20 & 1--30 $\|$ 119--151 & pET47b \\ \hline
        \caption[HCF-3R truncation constructs]{HCF-3R truncation constructs. \textsuperscript{$\ddagger$}Numbering corresponds to that shown in~\vref{tab:listhcf3rxxx}}
        \label{tab:listhcf3rtrunc}
        \end{longtable}
    \end{center}
%
\newpage
%
    \begin{center}
         \begin{longtable}{|c|c|c|c|} \hline
            Strain & Construct & Genotype & Plasmid\\ \hline
            JCJ-C207 & Wild-type OGT & ncOGT (23--1041) & pET24b \\ \hline
            JCJ-C220 & OGT (D554N) & ncOGT (23--1041), D554N & pET24b \\ \hline
            JCJ-C219 & OGT (D554A) & ncOGT (23--1041), D554A & pET24b \\ \hline
            JCJ-C217 & OGT (K842M) & ncOGT (23--1041), K842M & pET24b \\ \hline
            JCJ-C222 & OGT (H498A) & ncOGT (23--1041), H498A & pET24b \\ \hline
            JCJ-C221 & OGT (H558A) & ncOGT (23--1041), H558A & pET24b \\ \hline
            JCJ-C102 & hOGT4.5 ($\Delta$9 TPR)\textsuperscript{$\dagger$} & ncOGT (323--1041) & pET24b \\ \hline
            JCJ-C232 & hOGT4.5 (D554N)\textsuperscript{$\dagger$} & ncOGT (323--1041), D554N & pET24b \\ \hline
            JCJ-C156 & OGT5.5 ($\Delta$8 TPR)\textsuperscript{$\dagger$} & ncOGT (289--1041) & pET24b \\ \hline
            JCJ-C157 & OGT6.5 ($\Delta$7 TPR)\textsuperscript{$\dagger$} & ncOGT (255--1041) & pET24b \\ \hline
            JCJ-C186 & OGT7.0 ($\Delta$6.5 TPR) & ncOGT (238--1041) & pET24b \\ \hline
            JCJ-C187 & OGT7.5 ($\Delta$6 TPR) & ncOGT (221--1041) & pET24b \\ \hline
            JCJ-C188 & OGT8.0 ($\Delta$5.5 TPR) & ncOGT (203--1041) & pET24b \\ \hline
            JCJ-C189 & OGT8.5 ($\Delta$5 TPR) & ncOGT (187--1041) & pET24b \\ \hline
            JCJ-C190 & OGT9.0 ($\Delta$4.5 TPR) & ncOGT (169--1041) & pET24b \\ \hline
            JCJ-C191 & OGT9.5 ($\Delta$4 TPR) & ncOGT (153--1041) & pET24b \\ \hline
        \caption[List of OGT constructs employed in these studies]{List of OGT constructs employed in these studies. \textsuperscript{$\dagger$}Allele originally made by Michael B. Lazarus. Note: OGT7.0 ($\Delta$6.5 TPR), OGT8.5 ($\Delta$5 TPR) and OGT9.5 ($\Delta$4 TPR) yielded little soluble protein, presumably due to misfolding of the TPR domain.}
        \label{tab:ogtconstructs}
        \end{longtable}
    \end{center}
%
\newpage
%
\begin{table}
    \begin{center}
        \begin{tabular}{|c|c|c|c|}
        \hline
        Step & Time (min) & \%A\textsuperscript{$\dagger$} & \%B\textsuperscript{$\ddagger$} \\ \hline
        1 & 0 -- 3 & 100 & 0 \\ \hline
        2 & 3 -- 3.1 & 90 & 10 \\ \hline
        3 & 3.1 -- 17.3 & 77.5 & 22.5 \\ \hline
        4 & 17.3 -- 17.4 & 0 & 100 \\ \hline
        5 & 17.4 -- 22.4 & 40 & 60 \\ \hline
        6 & 22.4 -- 27.4 & 40 & 60 \\ \hline
        7 & 27.4 -- 29.4 & 100 & 0 \\ \hline
        8 & 29.4 -- 33 & 100 & 0 \\ \hline
        \end{tabular}
        \caption[LC gradient method (q-Exactive)]{LC gradient method (q-Exactive).~\textsuperscript{$\dagger$}Mobile phase ``A'' is 0.1\% formic acid in water. ~\textsuperscript{$\ddagger$}Mobile phase ``B'' is 0.1\% formic acid in acetonitrile.}
        \label{tab:gradmethod1}
    \end{center}
\end{table}
%
\begin{table}
    \begin{center}
        \begin{tabular}{|c|c|c|c|}
        \hline
        Step & Time (min) & \%A\textsuperscript{$\dagger$} & \%B\textsuperscript{$\ddagger$} \\ \hline
        1 & 0 & 97 & 3 \\ \hline
        2 & 2 & 97 & 3 \\ \hline
        3 & 30 & 55 & 45 \\ \hline
        4 & 35 & 30 & 70 \\ \hline
        5 & 35.1 & 97 & 3 \\ \hline
        6 & 45 & 97 & 3 \\ \hline
        \end{tabular}
        \caption[LC gradient method (q-ToF)]{LC gradient method (q-ToF).~\textsuperscript{$\dagger$}Mobile phase ``A'' is 0.1\% formic acid in water. ~\textsuperscript{$\ddagger$}Mobile phase ``B'' is 0.1\% formic acid in acetonitrile.}
        \label{tab:gradmethod2}
    \end{center}
\end{table}
%
\newpage
\hsp
%
\begin{table}
    \begin{center}
        \begin{tabular}{cc}
        \hline
                                                        & hOGT4.5 (D554N):UDP:CKII glycopeptide (ternary product)   \\ \hline
        \textbf{Data collection}                        &                                                           \\
        Space Group                                     & I121                                                      \\
        Cell dimensions                                 &                                                           \\
            \textit{a},\textit{b},\textit{c} (\AA)                                 & 98.35 137.19 153.07                                       \\
            $\alpha$, $\beta$, $\gamma$ ($^{\circ}$)    & 90.00 103.05 90.00                                        \\
        Resolution (\AA)                                & 40.93--2.05 (2.09--2.05)                                  \\
        \textit{R}\textsubscript{sym} or \textit{R}\textsubscript{merge}  & 0.097 (0.324)                                             \\
        \textit{I} / $\sigma$\textit{I}                                     & 5.9 (1.9)                                                 \\
        Completeness (\%)                               & 95.2 (86.3)                                               \\
        Redundancy                                      & 2.7 (2.3)                                                 \\ 
        \textbf{Refinement}                             &                                                           \\
        Resolution (\AA)                                & 40.925--2.05                                              \\ 
        Number of reflections                           & 117417                                                    \\ 
        \textit{R}\textsubscript{work} / \textit{R}\textsubscript{free}     & 0.2172 / 0.2374                                           \\ 
        Number of atoms                                 &                                                           \\ 
            Protein                                     & 11093                                                     \\ 
            Ligand/ion                                  & 93                                                        \\ 
            Water                                       & 772                                                       \\ 
        \textit{B}-factors                              &                                                           \\ 
            Protein                                     & 32.3                                                     \\ 
            Ligand/ion                                  & 21.8                                                        \\ 
            Water                                       & 33.6                                                       \\
        RMS deviations                                  & \\ 
            Bond lengths (\AA)                          & 0.004 \\ 
            Bond angles ($^{\circ}$)                    & 0.661 \\               
        \hline
    \end{tabular}
    \dsp
    \caption[Data collection and refinement statistics for hOGT4.5 (D554N):UDP:CKII glycopeptide ternary structure]{Data collection and refinement statistics for hOGT4.5 (D554N):UDP:CKII glycopeptide ternary structure. Values in parentheses are for the highest-resolution shell. One crystal was used for this structure.}
    \label{tab:d554n-xray-parameters}
    \end{center}
\end{table}
%
%
%